Truscreen GroupASX:TRU Current Ratio is 2.47 as of Mar. 2025, which is 33% below its 10-year median of 3.70. The stock has 6 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Truscreen Group ranks better than 63% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Truscreen Group's current ratio for the quarter that ended in Mar. 2025 was 2.47.
Truscreen Group has a current ratio of 2.47. It generally indicates good short-term financial strength.
The historical rank and industry rank for Truscreen Group's Current Ratio or its related term are showing as below:
ASX:TRU'
s Current Ratio Range Over the Past 10 Years
Min: 2.47 Med: 3.7 Max: 10.18
Current: 3.29
During the past 12 years, Truscreen Group's highest Current Ratio was 10.18. The lowest was 2.47. And the median was 3.70.
ASX:TRU's Current Ratio is ranked better than 63% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.475
vs ASX:TRU: 3.29
Truscreen Group (ASX:TRU) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Truscreen Group Current Ratio Related Terms
Truscreen Group Current Ratio Historical Data
* Premium members only.
The historical data trend for Truscreen Group's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TRU vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, Truscreen Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where Truscreen Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group (ASX:TRU) has a Current Ratio of 2.47 as of Mar. 2025. This is 33% below median its historical median of 3.70. Over the past decade, Truscreen Group's Current Ratio has ranged from 2.47 to 10.18. According to the industry distribution chart, Truscreen Group ranks #316 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 37%.
Is Truscreen Group's Current Ratio too high?
Truscreen Group's current Current Ratio of 2.47 is 33% below median its 10-year median of 3.70. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 10.18. The Medical Devices & Instruments industry median Current Ratio is 2.48. Truscreen Group's value of 2.47 is 0.2% below this industry median. Based on the distribution chart, Truscreen Group ranks #316 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Truscreen Group's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Truscreen Group ranks #316 out of 854 companies for Current Ratio. This puts Truscreen Group in the upper half of its industry. The industry median Current Ratio is 2.48. Truscreen Group's value of 2.47 is 0.2% below this benchmark. Historically, Truscreen Group's own Current Ratio has ranged from 2.47 to 10.18 over the past decade. While the company's 10-year median is 3.70 vs. the industry median of 2.48, Truscreen Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.48, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Truscreen Group's current Current Ratio of 2.47 is 0.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Truscreen Group's current Current Ratio is 2.47, which is 33% below median its own 10-year median of 3.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 30% below its estimated fair value. The current Current Ratio is 2.47, which is 33% below median its 10-year median of 3.70 and 0.2% below the Medical Devices & Instruments industry median of 2.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current Current Ratio is 2.47 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRU has been successfully added to your 